Arcus Biosciences, Inc. (RCUS) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$353M, a net margin of -142.9%; the best year in this period was 2021 with $53M.
Over the twelve months to September 30, 2026, revenue was $100M and net income -$453M.
Free cash flow was -$484M in fiscal 2025 and positive in 2 of the 10 years shown.
The diluted share count rose 12331% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100M | $247M | $258M | $117M | $112M | $383M | $78M | $15M | $8M | $1M | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$475M | -$386M | -$330M | -$340M | -$280M | $54M | -$124M | -$89M | -$55M | -$53M | -$18M |
| Net income | -$453M | -$353M | -$283M | -$307M | -$267M | $53M | -$123M | -$85M | -$50M | -$53M | -$18M |
| EPS (diluted) | $-3.64 | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | $-1.43 | $-29.03 | $-20.80 |
| R&D | $473M | $523M | $448M | $340M | $288M | $257M | $159M | $78M | $50M | $47M | $14M |
| Revenue growth | — | −4.3% | +120.5% | +4.5% | −70.8% | +391.0% | +420.0% | +79.6% | +491.2% | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$465M | -$482M | -$170M | -$306M | $438M | -$256M | $111M | -$73M | -$43M | -$25M | -$13M |
| Capital spending | -$1M | -$2M | -$6M | -$24M | -$6M | -$26M | -$3M | -$2M | -$4M | -$6M | -$4M |
| Free cash flow | -$466M | -$484M | -$176M | -$330M | $432M | -$282M | $108M | -$75M | -$47M | -$31M | -$17M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | $94000 | $0 | — | — |
| Stock-based pay | $65M | $60M | $76M | $73M | $65M | $55M | $22M | $9M | $4M | $495000 | $90000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $981M | $978M | $759M | $1.0B | $499M | $729M | $58M | $71M | $98M | $65M |
| Debt | — | $198M | $159M | $121M | $126M | $114M | $18M | — | — | — | — |
| Equity | — | $631M | $485M | $462M | $657M | $842M | $502M | $164M | $235M | -$72M | -$20M |
| Total assets | — | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B | $772M | $203M | $275M | $190M | — |
| Shares (diluted) | 127M | 107M | 90M | 74M | 72M | 74M | 55M | 44M | 35M | 2M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | -475.0% | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% | -159.0% | -591.4% | -656.8% | -3782.1% | — |
| Net margin | -453.0% | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | — |
| FCF margin | -466.0% | -195.9% | -68.2% | -282.1% | 385.7% | -73.6% | 138.5% | -502.6% | -559.6% | -2163.7% | — |
| ROIC | — | -46.6% | -40.5% | -46.1% | -28.2% | 5.5% | -18.8% | -42.7% | -18.4% | — | — |
| ROE | — | -55.9% | -58.4% | -66.5% | -40.6% | 6.3% | -24.5% | -51.6% | -21.1% | 73.4% | 89.9% |
Frequently asked questions
What is Arcus Biosciences’s annual revenue?
$247M in fiscal 2025 and $100M over the twelve months to September 30, 2026.
How much profit does Arcus Biosciences make?
Net income was -$353M in fiscal 2025 (net margin -142.9%).
Is Arcus Biosciences’s revenue growing?
No: revenue fell 4.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.